) The In Vivo Imaging Core will support all 3 programs in the SPORE by providing a unique, non-invasive evaluation of (1) receptors important in the growth and spread of ovarian cancer, (2) tumor targeting via adenoviral vectors, and (3) apoptosis pathways in conjunction with therapy evaluation. In addition, the Core will conduct studies of organ function. The infrastructure for the core already exists, having been established by competitive funding through an internal mechanism. Radiotracers already developed over the past two years will be utilized for the proposed imaging evaluations. The majority of the imaging experiments will be conducted in animal models. However, it is anticipated that following validation of the reporter system for imaging gene transfer in the animal model, this capability will be translated to the phase I clinical testing. The Core will support this part of the phase I testing, which will be possible since the radiopharmaceutical is an approved human agent. Imaging data provided by the Core will be complementary to other modes, such as immunohistology, to evaluate ovarian cancer. The advantages of imaging include the fact it is repeatable, non-invasive, and capable of evaluating the entire animal model (or human) over time. The Core has two dedicated gamma cameras for animal experimentation, with adjacent animal housing facilities (Isolators). These equipment and facilities, coupled with the expertise in radiochemistry, allow virtually any protein molecule to be radiolabeled with Tc-99m and used for imaging in animal models. The advantages to Tc-99m include its short half-life (6 hours), low cost, constant availability, and ease in imaging due to its abundant, low energy gamma-ray emission. To date, over 25 different protein molecules have been radiolabeled with Tc-99m by the Core?s scientists, including short peptides (e.g. for targeting E-selectin or somatostatin receptors), growth factors (FGF-1), antibodies, and soluble receptors. These radiolabeled proteins are subjected to stringent in vitro evaluations prior to conducting animal experimentation. Binding constants are determined by Scatchard analyses to insure correct interpretation of the in vivo imaging data.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083591-04
Application #
6660939
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-30
Project End
2003-09-29
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Ren, Yi A; Mullany, Lisa K; Liu, Zhilin et al. (2016) Mutant p53 Promotes Epithelial Ovarian Cancer by Regulating Tumor Differentiation, Metastasis, and Responsiveness to Steroid Hormones. Cancer Res 76:2206-18
Nelson, Carol A; Azure, Michael T; Adams, Christopher T et al. (2014) The somatostatin analog 188Re-P2045 inhibits the growth of AR42J pancreatic tumor xenografts. J Nucl Med 55:2020-5
Kim, Kenneth H; Dmitriev, Igor; O'Malley, Janis P et al. (2012) A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18:3440-51
Kimball, Kristopher J; Preuss, Meredith A; Barnes, Mack N et al. (2010) A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res 16:5277-87
Borovjagin, Anton V; McNally, Lacey R; Wang, Minghui et al. (2010) Noninvasive monitoring of mRFP1- and mCherry-labeled oncolytic adenoviruses in an orthotopic breast cancer model by spectral imaging. Mol Imaging 9:59-75
Szafran, April Adams; Folks, Karri; Warram, Jason et al. (2009) Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis. Cancer Biol Ther 8:1109-16
Matsumura, Noriomi; Huang, Zhiqing; Baba, Tsukasa et al. (2009) Yin yang 1 modulates taxane response in epithelial ovarian cancer. Mol Cancer Res 7:210-20
Bell, Walter C; Sexton, Katherine C; Grizzle, William E (2009) How to efficiently obtain human tissues to support specific biomedical research projects. Cancer Epidemiol Biomarkers Prev 18:1676-9
Meredith, Ruby F; Shen, Sui; Forero, Andres et al. (2008) A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med 49:279-84

Showing the most recent 10 out of 114 publications